The Ark Innovation ETF (NYSEMKT: ARKK) has been performing dreadfully this year, down 53% thus far. That's much worse than the S&P 500 and its 19% loss. The fund's focus has been on growth-oriented companies, many of which aren't posting strong and consistent profits. And as investors have been worrying about a possible recession, they've been moving away from such stocks.
The three stocks that are the Ark's best holdings right now are CRISPR Therapeutics (NASDAQ: CRSP) , Cerus (NASDAQ: CERS) , and Signify Health (NYSE: SGFY) . The one thing these stocks have in common: They're all in the healthcare industry .
Shares of CRISPR Therapeutics are down a very modest 2% this year. You could argue that after a hefty 50% drop in 2021, it may have bottomed out. However, there are also reasons now to be bullish on this growth stock.
For further details see:
The Best 3 Stocks in Cathie Wood's Ark ETF Have 1 Thing in Common